CA2467397A1 - Flavivirus vaccine delivery system - Google Patents

Flavivirus vaccine delivery system Download PDF

Info

Publication number
CA2467397A1
CA2467397A1 CA002467397A CA2467397A CA2467397A1 CA 2467397 A1 CA2467397 A1 CA 2467397A1 CA 002467397 A CA002467397 A CA 002467397A CA 2467397 A CA2467397 A CA 2467397A CA 2467397 A1 CA2467397 A1 CA 2467397A1
Authority
CA
Canada
Prior art keywords
replicon
protein
rna
virus
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002467397A
Other languages
English (en)
French (fr)
Inventor
Alexander A. Khromykh
Andreas Suhrbier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
REPLIKUN BIOTECH Pty Ltd
University of Queensland
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR9093A external-priority patent/AUPR909301A0/en
Priority claimed from AU2002950974A external-priority patent/AU2002950974A0/en
Application filed by REPLIKUN BIOTECH Pty Ltd, University of Queensland, Queensland Institute of Medical Research QIMR filed Critical REPLIKUN BIOTECH Pty Ltd
Publication of CA2467397A1 publication Critical patent/CA2467397A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002467397A 2001-11-26 2002-11-26 Flavivirus vaccine delivery system Abandoned CA2467397A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPR9093A AUPR909301A0 (en) 2001-11-26 2001-11-26 Flavivirus vaccine system
AUPR9093 2001-11-26
AU2002950974 2002-07-29
AU2002950974A AU2002950974A0 (en) 2002-07-29 2002-07-29 Flavivirus vaccine system
PCT/AU2002/001598 WO2003046189A1 (en) 2001-11-26 2002-11-26 Flavivirus vaccine delivery system

Publications (1)

Publication Number Publication Date
CA2467397A1 true CA2467397A1 (en) 2003-06-05

Family

ID=25646850

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002467397A Abandoned CA2467397A1 (en) 2001-11-26 2002-11-26 Flavivirus vaccine delivery system

Country Status (7)

Country Link
US (1) US20060204523A1 (enExample)
EP (1) EP1461441A4 (enExample)
JP (1) JP2005510244A (enExample)
CN (1) CN100392087C (enExample)
CA (1) CA2467397A1 (enExample)
NZ (1) NZ533237A (enExample)
WO (1) WO2003046189A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072274A1 (en) * 2003-01-30 2004-08-26 Shanghai Tengen Biomedical Co., Ltd. Virus-like particle vaccine containing dengue virus recombinant replicon as its carrier
AU2004245578B2 (en) * 2003-06-06 2008-10-30 Replikun Biotech Pty Ltd Flavivirus replicon packaging system
AU2003902842A0 (en) * 2003-06-06 2003-06-26 The University Of Queensland Flavivirus replicon packaging system
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
US20070036827A1 (en) * 2003-10-29 2007-02-15 The University Of Queensland West nile virus vaccine
WO2007098267A2 (en) * 2006-02-27 2007-08-30 The Board Of Regents Of The University Of Texas System Pseudoinfectious flavivirus and uses thereof
WO2009114207A2 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
CA2755257A1 (en) * 2009-03-16 2010-09-23 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccine vectors against respiratory syncytial virus
CA2804591C (en) * 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
SI2714071T1 (sl) * 2011-05-24 2019-11-29 Biontech Rna Pharmaceuticals Gmbh Individualizirana cepiva proti raku
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2013019603A2 (en) * 2011-07-29 2013-02-07 Inovio Pharmaceuticals, Inc. Linear expression cassettes and uses thereof
EP3105311A1 (en) 2014-02-10 2016-12-21 Univercells NV System, apparatus and method for biomolecules production
EP3352785A1 (en) * 2015-09-23 2018-08-01 Massachusetts Institute Of Technology Compositions and methods for modified dendrimer nanoparticle vaccine delivery
WO2018152158A1 (en) * 2017-02-14 2018-08-23 Shi Pei Yong Live attenuated zika virus with 3'utr deletion, vaccine containing and use thereof
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
AU2020395091A1 (en) * 2019-12-03 2022-07-28 The Council Of The Queensland Institute Of Medical Research Defective interfering particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
ES2345614T3 (es) * 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
NZ504725A (en) * 1997-11-28 2003-02-28 Crown In The Right Of The Quee Flavivirus expression and delivery system
US6893866B1 (en) * 1997-11-28 2005-05-17 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
WO2000014245A1 (en) * 1998-09-02 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Dengue viruses that are replication defective in mosquitos for use as vaccines
FR2794865B1 (fr) * 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
CA2380302C (en) * 1999-08-09 2013-02-26 Biochemie Gesellschaft M.B.H. Production of proteins by autoproteolytic cleavage
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
DK2278012T3 (en) * 2000-02-16 2015-12-07 Us Government Immunogenic dengue 2 virus chimeras
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines

Also Published As

Publication number Publication date
NZ533237A (en) 2005-11-25
CN100392087C (zh) 2008-06-04
HK1081987A1 (zh) 2006-05-26
CN1671851A (zh) 2005-09-21
US20060204523A1 (en) 2006-09-14
JP2005510244A (ja) 2005-04-21
WO2003046189A1 (en) 2003-06-05
EP1461441A4 (en) 2006-02-22
EP1461441A1 (en) 2004-09-29

Similar Documents

Publication Publication Date Title
KR101518309B1 (ko) 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
JP5602624B2 (ja) αウイルス構造タンパク質の発現のためのプロモーターレスカセット
CA2567254C (en) Tc-83-derived alphavirus vectors, particles and methods
US20060204523A1 (en) Flavivirus vaccine delivery system
Anraku et al. Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity
US20060280757A1 (en) Flavivirus vaccine delivery system
US20070036827A1 (en) West nile virus vaccine
CN113164582A (zh) 嵌合黄病毒丽沙病毒疫苗
Anraku et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines
AU2002342415B2 (en) Flavivirus vaccine delivery system
HK1081987B (en) Flavivirus vaccine delivery system
US20200316187A1 (en) Chimeric yellow fever zika virus strain
RU2816136C2 (ru) Химерные вакцины на основе вирусов родов flavivirus и lyssavirus
AU2004245578B2 (en) Flavivirus replicon packaging system
HK1084692B (en) Improved alphavirus replicons and helper constructs

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued